Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN208397 for Macular Edema in Retinal Vein Occlusion
NCT01027650Phase 2Completed
- Sponsor
- Allergan
- Start
- Mar 2010
- Primary completion
- Apr 2012
- Modality
- Carrier/Scaffold Proteins
- Countries
- 5
01
Overview
A Phase 2 trial of abicipar pegol in macular edema, retinal vein occlusion (RVO), sponsored by Allergan. Started Mar 2010; status: completed.
02
Drugs
abicipar pegol
03
Conditions
macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT01027650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027650.